Precigen (NASDAQ: PGEN) reported Q1 2026 results showing strong momentum for its FDA-approved product PAPZIMEOS, which generated $21.6 million in net product revenue in its first full quarter post-launch. The company achieved approximately 400 patient hub enrollments with 25% from community settings, secured broad payer coverage spanning over 90% of insured US lives, and received a permanent J-code for reimbursement. Net loss improved significantly to $7.9 million compared to $54.2 million in Q1 2025. With $56.7 million in cash and investments plus anticipated PAPZIMEOS revenue, the company expects to reach cash flow break-even by end of 2026.

Patient Capital Management increased its stake in Precigen by 10.2 million shares in Q3 2025, valuing the transaction at approximately $28.78 million. The investment represents 3.48% of the fund's assets under management, following Precigen's significant stock price surge after FDA approval of Papzimeos.

Two healthcare stocks, Precigen and Mineralys Therapeutics, have seen significant stock price increases recently due to FDA approval and promising clinical trial results in rare disease treatment and hypertension medication development.

Precigen has submitted a biologics license application to the FDA for PRGN-2012, a potential first treatment for recurrent respiratory papillomatosis. The submission is a significant step forward, as PRGN-2012 has received Breakthrough Therapy and Orphan Drug Designations from the FDA.

Precigen (NASDAQ:PGEN) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 1 0 0 0 Last 30D 2 0 0 0 0 1M Ago 2 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 1 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $8.17, a high estimate of $14.00, and a low estimate of $6.00. This current average has increased by 29.07% from the previous average price target of $6.33. Investigating Analyst Ratings: An Elaborate Study The analysis of recent analyst actions sheds light on the perception of Precigen by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Swayampakula Ramakanth HC Wainwright & Co. Maintains Buy $6.00 $6.00 Benjamin Burnett Stifel Raises Buy $10.00 $7.00 Swayampakula Ramakanth HC Wainwright & Co. Maintains Buy $6.00 $6.00 Benjamin Burnett Stifel Maintains Buy $7.00 - Jason Butler JMP Securities Maintains Market Outperform $14.00 - Swayampakula Ramakanth HC Wainwright & Co. Maintains Buy $6.00 - Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Precigen. This information offers a ...Full story available on Benzinga.com

Read about the upcoming Wall Street events, earnings reports, conferences, and IPOs for the week ahead.

Precigen (PGEN) delivered earnings and revenue surprises of -11.11% and 30.84%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 0% and 47.62%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance. FactSet Research posted adjusted earnings of $4.22 per share, beating market estimates of $3.88 per share. The company’s quarterly sales came in at $545.95 million, missing expectations of $546.80 million, according to data from Benzinga Pro. FactSet Research shares dipped 5.2% to $462.36 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Yield10 Bioscience, Inc. (NASDAQ: YTEN) shares jumped 136.7% to $0.5751 after the company announced that the USDA-APHIS Biotechnology Regulatory Services determined that the Camelina sativa varieties may be planted and bred in the United States. Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) shares jumped 101.7% to $2.6850 after falling 11% on Wednesday. CuriosityStream Inc. (NASDAQ: CURI) rose 63.2% to $2.6850 after the company reported financial results for fourth quarter. Portage Biotech Inc. (NASDAQ: PRTG) gained 53.7% to $0.7525. Lufax Holding Ltd (NYSE: LU) climbed 41.3% to $4.76 following fourth-quarter results. Asset Entities Inc. (NASDAQ: ASST) shares climbed 37% to $0.7173 after the company announced that it entered into an agreement with Zendrop. Cazoo Group Ltd (NYSE: CZOO) gained 33% to $4.6475. Guess?, Inc. (NYSE: GES) shares rose 23.1% to $31.95 as the company reported better-than-expected fourth-quarter financial results and declared a special dividend of $2.25 per share. Nortech Systems Incorporated (NASDAQ: NSYS) surged 22.3% to $13.35 after the company reported fourth-quarter results. JOANN Inc. (NASDAQ: JOAN) gained 20.8% to $0.1631. Aemetis, Inc. (NASDAQ: AMTX) climbed 18.4% to $4.3238 after the company announced approval by the U.S. Citizenship and Immigration Services for a $200 million of EB-5 program investment for the Riverbank sustainable aviation fuel, production plant, the dairy renewable natural gas project, the ...

U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 45 points on Monday. Shares of monday.com Ltd. (NASDAQ: MNDY) fell sharply in today’s pre-market trading after the company reported fourth-quarter financial results. Monday.com posted adjusted earnings of 65 cents per share on sales of $202.57 million. monday.com shares dipped 9% to $214.69 in pre-market trading. Here are some big stocks recording losses in today’s pre-market trading session. AN2 Therapeutics, Inc. (NASDAQ: ANTX) shares dipped 72% to $5.59 in pre-market trading as the company said it will voluntarily pause ...

Shares of Amtech Systems, Inc. (NASDAQ: ASYS) rose sharply in today’s pre-market trading after the company reported upbeat results for its first quarter on Friday. Amtech Systems posted an adjusted loss of 4 cents per share, compared to market estimates for a loss of 26 cents per share. The company’s quarterly sales came in at $24.92 million topping expectations of $22.25 million, according to data from Benzinga Pro. Amtech Systems shares surged 7.6% to $3.70 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Millennium Group International Holdings Limited (NASDAQ: MGIH) gained 142.7% to $2.50 in pre-market trading. YC 1926 (BVI) Limited reported an 88.89% stake in a 13G filing on Friday. DIH Holdings US, Inc. (NASDAQ: DHAI) gained 94% to $2.51 in pre-market trading. DIH Holding US secured $1.5 million in private placement financing from OrbiMed. SuperCom Ltd. (NASDAQ: SPCB) shares jumped 52.6% to $0.2802 in pre-market trading. SuperCom recently disclosed that it has secured a new contract with an established California services provider in the judicial sector. SeaStar Medical Holding Corporation (NASDAQ: ICU) ...

Shares of Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) rose sharply during Tuesday’s session after the company released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs). Longboard Pharmaceuticals shares jumped 199.7% to $18.07 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers Akso Health Group (NASDAQ: AHG) surged 85% to $1.2946. Polished.com Inc. (NYSE: POL) gained 45% to $8.77. Dogness (International) Corporation (NASDAQ: DOGZ) jumped 40% to $7.42. Cue Health Inc. (NASDAQ: HLTH) gained 36.8% to $0.2224 after falling 42% on Friday. Voyager Therapeutics, Inc. (NASDAQ: VYGR) surged 34% to $11.38 after the company announced a strategic collaboration and capsid license agreement with Novartis to advance potential gene therapies for Huntington's disease and spinal muscular atrophy. RiskOn International, Inc. (NASDAQ: ROI) shares climbed 33.5% to $0.4450 after gaining around 17% on Friday. RiskOn International recently said it expects to announce its new generative AI platform and unveil a principal technology partner on Jan. 3. Soligenix, Inc. (NASDAQ: SNGX) shares gained 33.4% to $1.01. Soligenix announced publication demonstrating complete protection against filovirus disease in nonhuman primate models of ebola and marburg viruses. SenesTech, Inc. (NASDAQ: SNES) gained 22.2% to $1.56. SenesTech announced the expansion of its distribution agreement with Pesterminators Pvt Ltd to include the deployment of EvolveTM. Brooge Energy Limited (NASDAQ: BROG) jumped 17.1% to $4.31. Brooge Energy recently announced that it reached a settlement with the SEC where it agreed to pay a $5 million penalty and cease any future violations. Lyell Immunopharma, Inc. (NASDAQ: LYEL) gained 16.9% to $2.26. Wheels Up Experience Inc. (NYSE: